Plaintiffs Battle For Lead Role In Vytorin ERISA Suit

Law360, New York (July 1, 2008, 12:00 AM EDT) -- The lead plaintiffs in a shareholder lawsuit over Merck & Co. Inc.'s shelved Vioxx painkiller have asked to assume the role of lead plaintiff in a new proposed multidistrict litigation over allegations that the company covered up evidence that its cholesterol drug Vytorin was less effective than advertised.

In a motion filed last Monday in the U.S. District Court for the District of New Jersey, the plaintiffs asked that Schatz Nobel Izard PC and Schiffrin Barroway Topaz & Kessler LLP, who represent them in the Vioxx...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.